TMDX — TransMedics Group, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1756262 ·
Last close
$73.83
Market Cap
$2.55B
52W High
$120.91
52W Low
$60.10
ADV30
1,307,738
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 173,933,000 | 101,161,000 | 13,297,000 | 7,315,000 | 1,434,820,000 | 461,739,000 | 940,813,000 |
| Dec 2025 | 160,764,000 | 93,414,000 | 21,273,000 | 105,383,000 | 1,068,373,000 | 488,366,000 | 595,273,000 |
| Sep 2025 | 143,823,000 | 84,575,000 | 23,300,000 | 24,319,000 | 946,032,000 | 466,174,000 | 590,832,000 |
| Jun 2025 | 157,370,000 | 96,589,000 | 36,567,000 | 34,907,000 | 890,522,000 | 400,575,000 | 572,421,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$220,228,000
Investing CF
$-68,870,000
Financing CF
$17,591,000
CapEx
$-68,870,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$4.40
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-270,635,000
Inventory
$49,890,000
Receivables
$90,727,000
ST Investments
—
EBIT TTM
$106,822,000
Pretax Income TTM
$89,331,000
Interest Exp TTM
$17,491,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$635,889,984
EBITDA
$125,349,000
Free Cash Flow
$108,822,248
Enterprise Value
$2,953,308,160
Total Cash
$461,739,008
Total Debt
$863,414,976
Shares Out
34,560,911
Trailing EPS
$4.37
Book Value
$13.81
ROE
45.2%
ROA
5.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 605,494,000 | 108,583,000 | 190,291,000 | 1,068,373,000 | 595,273,000 | — | 192,840,000 |
| Dec 2024 | 441,540,000 | 37,496,000 | 35,464,000 | 804,076,000 | 575,473,000 | — | 48,803,000 |
| Dec 2023 | 241,623,000 | -28,727,000 | -25,028,000 | 706,047,000 | 568,845,000 | — | -13,028,000 |
| Dec 2022 | 93,459,000 | -31,437,000 | -36,231,000 | 277,147,000 | 89,772,000 | — | -45,817,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.30
Max Pain — expiry 2026-07-17
max pain strike: $75.00 · spot: $76.51 · call oi: 7,452 · put oi: 10,402
Expected Move to 2026-07-17:
±$9.45
(12.35%) —
implied range
$67.06 –
$85.96
· ATM straddle on $75.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $2.56B | $87.01 | — |
| AXGN | Axogen, Inc. | $2.38B | $44.69 | — |
| HTFL | Heartflow, Inc. | $2.97B | $34.48 | — |
| ITGR | Integer Holdings Corp | $3.04B | $89.54 | — |
| LMAT | LEMAITRE VASCULAR INC | $2.10B | $91.95 | — |
News headlines (Yahoo Finance, 1h cache)
Will Analyst Focus on TransMedics’ OCS Platform and Financial Metrics Change TransMedics Group’s (TMDX) Narrative?
2026-06-06 20:17 · Yahoo
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
2026-06-04 15:30 · Yahoo
Reasons to Retain TransMedics Stock in Your Portfolio for Now
2026-05-28 16:59 · Yahoo
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-05-21 20:05 · Yahoo
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
2026-05-19 20:05 · Yahoo
Assessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price Decline
2026-05-10 05:15 · Yahoo
TransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
2026-05-08 15:00 · Yahoo
Glucotrack Submits Blood Glucose Monitoring Technology to FDA
2026-05-07 19:50 · Yahoo
My Top 3 Stocks to Buy in May
2026-05-07 09:04 · Yahoo
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
2026-05-06 15:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.